Guanylhydrazones useful for treating diseases associated with T cell activation
AssigneeCytokine PharmaSciences, Inc.
InventorsKevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
Life of this patent
Estimating the term…
Abstract
There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
Claims3
A method of treating a disorder or disease characterized by T cell activation, comprising administering to a subject in need thereof an effective amount of an agent, other than an inhibitor of kinase activity of the p38 MAPK, that inhibits gene expression of a component of the p38 MAPK signaling pathway.
A method of treating a disorder or disease characterized by T cell activation, comprising administering to a subject in need thereof an agent, other than an inhibitor of kinase activity of the p38 MAPK, that inhibits expression of the p38 MAPK gene.
Dependencies are inferred from the claim text.